Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression - Laboratoire Inflammation, Tissus épithéliaux et Cytokines Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2018

Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression

Résumé

Cutaneous squamous cell carcinoma (cSCC) is the second most common keratinocyte malignancy and accounts for 20% of skin cancer deaths. Cancer is closely related to inflammation, but the contribution of the tumor microenvironment to cSCC development is poorly understood. We previously showed that oncostatin M (OSM), a cytokine belonging to the IL-6 family, promotes normal keratinocyte proliferation and migration, skin inflammation, and epidermal hyperplasia, both in vitro and in vivo. Here, we show that OSM is overexpressed in human cSCC and is associated with type 1 immune polarization. In vitro, OSM induced STAT-3 and ERK signaling, modified the expression of genes involved in cytokine signaling, proliferation, inhibition of apoptosis, and immune responses, and promoted proliferation and migration of malignant keratinocyte PDVC57 cells. PDVC57 cells grafted in the skin of mice led to rapid cSCC development, associated with OSM expression by tumor-infiltrating neutrophils. Finally, the absence of OSM (OSM-KO mice) led to a 30% reduction of tumor size and reduced M2 polarization in the tumor microenvironment. Globally, these results support a pro-tumoral role of OSM in cSCC development and suggest that a new therapeutic approach targeting this cytokine could be considered.

Domaines

Cancer
Fichier principal
Vignette du fichier
oncotarget-v9i92-26355.pdf (5.27 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-04186396 , version 1 (19-03-2024)

Identifiants

Citer

Marie Simonneau, Eric Frouin, Vincent Huguier, Cynthia Jermidi, Jean François Jégou, et al.. Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression. Oncotarget, 2018, 9 (92), pp.36457-36473. ⟨10.18632/oncotarget.26355⟩. ⟨hal-04186396⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More